Neural and Antidepressant Effects of Propofol (Phase 2)

Withdrawn before enrolling · Phase 2/Phase 3

Conditions studied: Treatment Resistant Depression

In brief

Moderate-intensity propofol treatments will be administered to participants who are non-responders at the end of Phase 1.

Key facts

Study ID

NCT03923361

Run by

University of Utah

People needed

0

Starts

2019-04-16

Expected to finish

2024-07-01

Last updated by the study team

2019-12-18

Who can join

Age: 18 and older, up to 55. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-55
• Diagnosis of major depressive disorder or bipolar disorder
• Current moderate-to-severe depressive episode
• Episode duration more than 2 months and less than 5 years
• Failure of at least 2 adequate antidepressant medication trials within the past 2 years
• Body mass index < 40
• 16-item Quick Inventory of Depressive Symptomatology, self-rated > 10

You may not qualify if…

• Contraindication to propofol or midazolam
• Daily use of benzodiazepine, opioid, ACE inhibitor, or ARB medication
• Symptomatic coronary artery disease or heart failure
• Poorly controlled hypertension or diabetes
• Abnormal kidney or liver function
• Pregnant or breast feeding
• Traumatic brain injury or significant neurologic signs (past year)
• Substance use disorder (past year)
• Obsessive compulsive disorder (current)
• Post-traumatic stress disorder (current)
• Schizophrenia-spectrum disorder (lifetime)
• Neurocognitive disorder (current)
• Personality disorder as a current focus of treatment
• ECT within the past 3 months
• Inappropriate for ECT, or poor response to ECT within the past 5 years
• Incompetent to provide consent

Where it is running

• Univeristy Neuropsychiatric Institute — Salt Lake City, Utah, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.